X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation. X. Long Zheng, MD, PhD: What is acquired TTP? TTP ...

Adzynma is a purified recombinant form of the ADAMTS13 protein designed to replace the missing or deficient ADAMTS13 enzyme. The Food and Drug Administration (FDA) has approved Adzynma for ...

A team led by investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, used a new drug to save the life of a patient with immune thrombotic ...

A 27-year-old patient with a history of severe obstetrical complications and arterial thrombosis received a diagnosis of hereditary thrombotic thrombocytopenic purpura (TTP) due to severe ADAMTS13 ...

Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...

Purpose. A case of a patient who developed thrombotic thrombocytopenic purpura (TTP) after consuming a weight-loss product containing green tea is reported. Summary. A 38-year-old, 68-kg Caucasian ...

Please provide your email address to receive an email when new articles are posted on . With the continual growth of the number of cytotoxic and targeted chemotherapeutics, as well as novel ...

Inhibitory autoantibodies against ADAMTS13, a metalloproteinase enzyme that cleaves von Willebrand factor, are associated with the majority of nonfamilial cases of thrombotic thrombocytopenic purpura ...

In a new study by Yale Cancer Center (YCC) researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care ...

Please provide your email address to receive an email when new articles are posted on . In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

Results showed 80% of pediatric patients achieved clinical remission. The Food and Drug Administration (FDA) has expanded the approval of Cablivi ® (caplacizumab-yhdp) to include treatment of ...